n recent years, Accelerator Mass Spectrometry (AMS) has been applied to an increasingly broader range of applications within the Life Science and Pharmaceutical industries. Specific applications within drug development include AMS-based preclinical development (PK/ADME), Phase 0 (microdosing) and Phase 1 (metabolite profiling). Widespread adoption of these AMS-driven applications requires the industry to address specific issues related to the AMS platform. These issues include access to and availability of AMS instruments, outsourcing vs. in-house decisions, study design and regulatory issues, integration with internal multidisciplinary support teams, quality metrics, cost vs., compelling value, turnaround time and data standardization. Accium BioSciences will address each of these issues and briefly present the practical side of building a fully-capable and scalable BioPharma AMS service facility in the U.S. The facility features a National Electrostatics Model 1.5SDH-1 Pelletron Accelerator and associated equipment for AMS. Finally, biolaboratory-related issues will be discussed and practical guidelines provided for preparing a low dose bioscience study.
See more of AMS in Low Dose Biosciences Posters
See more of The 10th International Conference on Accelerator Mass Spectrometry (September 5-10, 2005)